Qingfen Kang – Trademark Portfolio

Entity Type: 01

Qingfen Kang holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 1 filings in this category. The portfolio also extends into Class 28 (Toys & Sporting Goods) across 2 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include ZOOMOPA and TORCHALO. The owner is based in Hunan.

Wentang Town, Xinhua County

No.003,Fourth Village Group,Shijing Vil.

Hunan 417600 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

ZOOMOPA
ZOOMOPA
Registered 2025
TORCHALO
TORCHALO
Registered 2024

Trademark Classifications

Qingfen Kang's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (1 filing)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

28
Toys & Sporting Goods (1 filing)

Games and playthings; gymnastic and sporting articles; decorations for Christmas trees

Frequently Asked Questions

How many trademarks does Qingfen Kang have?

Qingfen Kang has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Qingfen Kang file in?

Qingfen Kang files trademarks across 2 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 28 (Toys & Sporting Goods). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are Qingfen Kang's most well-known trademarks?

Qingfen Kang's registered trademark portfolio includes well-known marks such as ZOOMOPA and TORCHALO. These are among 2 currently registered trademarks in the portfolio.

What is Qingfen Kang's trademark registration success rate?

Qingfen Kang has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.